10-Q: Citius Pharmaceuticals Reports Q2 2025 Results Amidst Going Concern Uncertainty

Sentiment:

Quarterly Report 14 May 2025 4:30 PM

📋All filings for Citius Pharmaceuticals, INC

Citius Pharmaceuticals reports a net loss of $11.5 million for the three months ended March 31, 2025, and acknowledges substantial doubt about its ability to continue as a going concern.

Capital raiseThe company acknowledges the need to raise additional capital to fund operations beyond May 2025.The company is exploring capital raise initiatives and strategic alternatives for its subsidiary, Citius Oncology.The company completed a registered direct offering on April 2, 2025, raising net proceeds of approximately $1.735 million.The company is dependent on securing additional financing through equity, debt, strategic relationships, or out-licensing of product candidates.

Worse than expectedThe company's cash position is critically low, raising substantial doubt about its ability to continue as a going concern.The company reported a net loss of $11.5 million for the three months ended March 31, 2025, which is worse than the $8.5 million net loss for the same period in 2024.The company's accumulated deficit has increased to $222.1 million.The company is dependent on future capital raises and LYMPHIR sales to fund its operations, which is a high-risk situation.

Summary

Citius Pharmaceuticals reported a net loss of $11.5 million for the three months ended March 31, 2025, compared to a net loss of $8.5 million for the same period in 2024.
For the six months ended March 31, 2025, the company's net loss was $21.8 million, compared to $17.8 million for the same period in 2024.
The company's research and development expenses for the three months ended March 31, 2025, were $3.8 million, compared to $3.6 million in 2024.
General and administrative expenses for the three months ended March 31, 2025, were $4.8 million, compared to $4.3 million in 2024.
The company's cash and cash equivalents as of March 31, 2025, were $26,410.
The company acknowledges substantial doubt about its ability to continue as a going concern, estimating that current cash resources will only fund operations through May 2025.
Citius is exploring capital raise initiatives and strategic alternatives for its subsidiary, Citius Oncology.
The company is dependent on obtaining regulatory approval for Mino-Lok and generating revenue from LYMPHIR sales, as well as securing additional financing.
A reverse stock split of 1-for-25 was executed on November 25, 2024, to regain compliance with Nasdaq listing requirements.
The company completed a registered direct offering on April 2, 2025, raising net proceeds of approximately $1.735 million.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the going concern warning, low cash position, and increasing net losses. While there are some positive developments, such as the FDA approval for LYMPHIR, the overall financial situation is precarious.

Positives

Citius Oncology received FDA approval for LYMPHIR in August 2024.
The company held a Type C meeting with the FDA to discuss the results of the Phase 3 study and to obtain the FDAs view on development plans for Mino-Lok.
The FDA provided clear, constructive, and actionable guidance during the discussion, underscoring a pathway to support a future New Drug Application (NDA) submission for Mino-Lok.
Citius Oncology entered into a letter agreement with Eisai on March 28, 2025, to establish a payment schedule for a $5.9 million milestone payment and unpaid invoices.
The company completed a registered direct offering on April 2, 2025, raising net proceeds of approximately $1.735 million.

Negatives

Citius Pharmaceuticals reports a net loss of $11.5 million for the three months ended March 31, 2025, and $21.8 million for the six months ended March 31, 2025.
The company's cash and cash equivalents as of March 31, 2025, were $26,410.
The company acknowledges substantial doubt about its ability to continue as a going concern, estimating that current cash resources will only fund operations through May 2025.
Citius Oncology has a $22.5 million milestone payment remaining due to Dr. Reddy's as of March 31, 2025.
The company has minimum purchase commitments of approximately $17.3 million with a contract manufacturing organization through 2026.
The company has minimum purchase commitments of approximately $4.5 million with two other vendors for the completion and packaging of finished drug products through 2026.

Risks

The company's limited cash resources raise substantial doubt about its ability to continue as a going concern.
The company is dependent on obtaining regulatory approval for Mino-Lok and generating revenue from LYMPHIR sales.
The company needs to obtain substantial additional financing to meet its obligations and fund operations.
There is no assurance that Citius Oncology will be successful in raising the needed capital or that the proceeds will be received in an amount or in a timely manner to support its operations.
The company faces risks related to the development of research and development stage products, regulatory approval, market acceptance, competition, dependence on key personnel and suppliers, and compliance with regulations.
The company is a guarantor of Citius Oncologys payment obligations, increasing its financial risk.
The company is subject to risks associated with commercial manufacturing contracts, including minimum purchase commitments and potential price increases.

Future Outlook

The company's future operations depend on obtaining regulatory approval for Mino-Lok, generating revenue from LYMPHIR sales, and securing additional financing through equity, debt, strategic relationships, or out-licensing of product candidates. The company expects research and development expenses to decrease in fiscal 2025 as it focuses on commercializing LYMPHIR and has completed the Phase 3 trial for Mino-Lok.

Industry Context

Citius Pharmaceuticals operates in the competitive biopharmaceutical industry, facing challenges common to companies in this sector, including securing funding, navigating regulatory approvals, and achieving market acceptance for its products. The company's focus on critical care products and oncology positions it within areas of significant unmet medical need, but also heightened competition from larger, more established pharmaceutical companies.

Comparison to Industry Standards

Given the limited cash position of $26,410 and the going concern warning, Citius Pharmaceuticals' financial situation is significantly weaker than many of its peers in the biopharmaceutical industry.
Comparable companies typically maintain sufficient cash reserves to fund operations for at least 12-24 months.
For example, companies like Madrigal Pharmaceuticals (MDGL) or Viking Therapeutics (VKTX), which are also in clinical development stages, have recently raised substantial capital to support their clinical programs and commercial preparations.
Citius's reliance on future capital raises and LYMPHIR sales for continued operations is a higher-risk profile compared to companies with more diversified revenue streams or stronger balance sheets.
The milestone payments due to Dr. Reddy's and Eisai upon LYMPHIR approval are standard in the industry for licensing agreements, but the company's ability to meet these obligations is uncertain given its current financial constraints.
The company's operating lease commitments and commercial manufacturing contracts are also typical for biopharmaceutical companies, but the magnitude of these commitments relative to Citius's cash position raises concerns about its financial flexibility.

Stakeholder Impact

Shareholders face significant risk due to the company's going concern uncertainty and dependence on future capital raises.
Employees face uncertainty regarding job security due to the company's financial situation.
Customers (patients) may face uncertainty regarding the availability of LYMPHIR if the company is unable to continue operations.
Suppliers and creditors face risk of non-payment due to the company's financial constraints.

Next Steps

The company needs to secure additional financing to fund operations beyond May 2025.
The company needs to successfully launch and generate substantial revenue from LYMPHIR sales.
The company needs to obtain regulatory approval for Mino-Lok.
Citius Oncology needs to evaluate strategic alternatives aimed at maximizing shareholder value.
The company needs to address the outstanding milestone payment obligations for LYMPHIR.
The company needs to manage the minimum purchase commitments under the Citius Oncology agreements for the manufacture and supply of LYMPHIR.

Key Dates

Date	Description
2014-09-12	Citius Pharmaceuticals acquired Citius Pharmaceuticals, LLC as a wholly-owned subsidiary.
2016-03-30	Citius Pharma acquired Leonard-Meron Biosciences, Inc. (LMB) as a wholly-owned subsidiary.
2019-07-01	Citius Pharma entered into a 76-month lease for office space in Cranford, NJ.
2020-09-11	Citius Pharma formed NoveCite, Inc., a Delaware corporation.
2020-10-06	NoveCite entered into a license agreement with Novellus Therapeutics Limited.
2021-08-23	Citius Pharma formed Citius Acquisition Corp. (later Citius Oncology) as a wholly-owned subsidiary.
2021-09-01	Citius Pharma assigned agreements to Citius Oncology effective April 1, 2022.
2021-09-01	Citius Pharma entered into an asset purchase agreement with Dr. Reddys and a license agreement with Eisai to acquire an exclusive license of E7777 (denileukin diftitox).
2022-04-01	Citius Pharma transferred assets related to LYMPHIR to Citius Oncology, which began operations.
2023-04-29	Citius Oncology adopted the 2023 Citius Oncology Omnibus Stock Incentive Plan.
2023-10-23	Citius Pharma and Citius Oncology entered into a merger agreement with TenX Keane Acquisition.
2024-08-02	Citius Oncology reserved an additional 15,000,000 common shares of Citius Oncology for issuance under the 2024 Citius Oncology Omnibus Stock Incentive Plan.
2024-08-08	The FDA approved the BLA for LYMPHIR.
2024-08-12	Merger Sub merged with and into Citius Oncology, with Citius Oncology surviving as a wholly owned subsidiary of TenX (the Merger) which was subsequently renamed Citius Oncology Sub.
2024-08-12	The Company entered into a sales agreement with HC Wainwright, to sell, from time to time during the term of the agreement the Companys common shares.
2024-11-15	The Company entered into an agreement with certain institutional investors for the issuance and sale, in a registered direct offering of 480,000 shares of the Companys common stock and warrants to purchase 480,000 shares of common stock.
2024-11-25	The Company executed a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 (Reverse Stock Split).
2024-12-18	The Company received notification that it had regained compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Stock Market LLC.
2025-01-07	The Company entered into an agreement with certain institutional investors for the issuance and sale, in a registered direct offering of 743,496 shares of the Companys common stock and warrants to purchase 743,496 shares of common stock.
2025-02-28	We extended the lease until February 28, 2030.
2025-03-28	Citius Oncology and Eisai entered into a letter agreement that amended the license agreement to provide for a payment schedule to Eisai for the milestone payment and certain unpaid invoices.
2025-03-31	End of the quarterly period.
2025-04-02	The Company sold 465,000 shares of common stock, and pre-funded warrants to purchase 1,274,131 shares of common stock at an offering price of $1.15 and $1.1499, respectively.
2025-04-17	The Company entered into a Subscription and Investment Representation Agreement (the Subscription Agreement) with Leonard Mazur (the Purchaser), the Chairman and Chief Executive Officer of the Company, pursuant to which the Company agreed to issue and sell one share of the Companys newly designated Series A Preferred Stock, par value $0.001 per share (the Series A Preferred Stock), to the Purchaser for a purchase price of $100.
2025-06-09	Special meeting of the stockholders of the Company (the Special Meeting), which has been called by the board of directors of the Company (the Board) for June 9, 2025, for the purpose of approving an amendment to the Companys Articles of Incorporation, as amended, to increase the number of shares of the Companys authorized common stock from 16,000,000 to 250,000,000 (the Authorized Share Increase).
2025-07-15	Citius Oncology has agreed to pay Eisai on or before July 15, 2025, an aggregate amount of $2,535,318 and thereafter on the 15th of each of the next four months to pay Eisai $2,350,000 and make a final payment of $2,197,892 to Eisai on or before December 15, 2025, in each case with interest on each obligation from its original due date through the date of actual payment under the letter agreement at the rate of 2% per annum.
2025-12-15	Citius Oncology has agreed to pay Eisai on or before July 15, 2025, an aggregate amount of $2,535,318 and thereafter on the 15th of each of the next four months to pay Eisai $2,350,000 and make a final payment of $2,197,892 to Eisai on or before December 15, 2025, in each case with interest on each obligation from its original due date through the date of actual payment under the letter agreement at the rate of 2% per annum.

Keywords

Citius Pharmaceuticals, LYMPHIR, Mino-Lok, Financial Results, Going Concern, Capital Raise, FDA Approval, Biopharmaceutical, CTCL, 10-Q Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.